In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: Ertapenem for treatment of gonorrhea?

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3603-3609

  Unemo, Magnus ^a   Golparian, Daniel ^a   Limnios, Athena ^b   Whiley, David ^c   Ohnishi, Makoto ^d   Lahra, Monica M ^b   Tapsall, John W ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c Queensland Children's Medical Research Institute   (Australia)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CEFTRIAXONE; ERTAPENEM; MTRB PROTEIN; PENA PROTEIN; PENB PROTEIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTRIAXONE; DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE;

EID: 84862583917     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00326-12     Document Type: Article

References (62)

1. Ameyama S, et al. 2002. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob. Agents Chemother. 46:3744-3749.
2. Arguedas A, et al. 2009. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. Int. J. Antimicrob. Agents 33:163-167.
3. Barry PM, Klausner JD. 2009. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin. Pharmacother. 10:555-577.
4. Berglund T, Unemo M, Olcén P, Giesecke J, Fredlund H. 2002. One year of Neisseria gonorrhoeae isolates in Sweden: the prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure. Int. J. STD AIDS 13:109-114.
5. Bignell C, Fitzgerald M, Guideline Development Group. 2011. UK national guideline for the management of gonorrhoea in adults, 2011. Int. J. STD AIDS 22:541-547.
6. Bolan GA, Sparling PF, Wasserheit JN. 2012. The emerging threat of untreatable gonococcal infection. N. Engl. J. Med. 366:485-487.
7. Burkhardt O, Derendorf H, Welte T. 2007. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin. Pharmacother. 8:237-256.
8. Centers for Disease Control and Prevention (CDC). 2011. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates - United States, 2000-2010. MMWR Morb. Mortal. Wkly. Rep. 60:873-877.
9. Chisholm SA, et al. 2010. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J. Antimicrob. Chemother. 65:2141-2148.
10. Chisholm SA, et al. 2011. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J. Antimicrob. Chemother. 66:592-595.
11. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing, 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Cole MJ, et al. 2011. The European gonococcal antimicrobial surveillance programme, 2009. Euro. Surveill. 16:pii=19995. http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=19995.
13. Congeni BL. 2010. Ertapenem. Expert Opin. Pharmacother. 11:669-672.
14. Deguchi T, et al. 2003. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J. Infect. Chemother. 9:35-39.
15. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. 2012. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with various high-level antimicrobial resistance - potential treatment option for gonorrhea? Antimicrob. Agents Chemother. 56:2739-2742.
16. Golparian D, Hellmark B, Fredlund H, Unemo M. 2010. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex. Transm. Infect. 86:454-460.
17. Hagman KE, et al. 1995. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 141:611-622.
18. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. 2011. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro. Surveill. 16:pii=19833. http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19833.
19. Ito M, et al. 2005. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in central Japan. Antimicrob. Agents Chemother. 49:137-143.
20. Jimenez-Cruz F, et al. 2002. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 60:16-22.
21. Kirkcaldy RD, Ballard RC, Dowell D. 2011. Gonococcal resistance: are cephalosporins next? Curr. Infect. Dis. Rep. 13:196-204.
22. Kubanova A, et al. 2010. The Russian gonococcal antimicrobial susceptibility programme (RU-GASP) - national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Euro. Surveill. 15:pii=19533. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19533.
23. Lee SG, et al. 2010. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J. Antimicrob. Chemother. 65:669-675.
24. Lewis DA. 2010. The gonococcus fights back: is this time a knock out? Sex. Transm. Infect. 86:415-421.
25. Lindberg R, Fredlund H, Nicholas R, Unemo M. 2007. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob. Agents Chemother. 51:2117-2122.
26. Livermore DM, et al. 2004. Activity of ertapenem against Neisseria gonorrhoeae. J. Antimicrob. Chemother. 54:280-281.
27. Livermore DM, Sefton AM, Scott GM. 2003. Properties and potential of ertapenem. J. Antimicrob. Chemother. 52:331-344.
28. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. 2004. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J. Infect. Dis. 189:1497-1505.
29. Martin I, et al. 2011. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009. Sex. Transm. Dis. 38:892-898.
30. Nakayama SI, et al. 2012. Molecular analyses of TEM genes and their corresponding penicillinase-producing Neisseria gonorrhoeae isolates in Bangkok, Thailand. Antimicrob. Agents Chemother. 56:916-920.
31. Newman LM, Moran JS, Workowski KA. 2007. Update on the management of gonorrhea in adults in the United States. Clin. Infect. Dis. 44(Suppl. 3):S84-S101.
32. Ohnishi M, et al. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob. Agents Chemother. 55:3538-3545.
33. Ohnishi M, et al. 2011. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg. Infect. Dis. 17:148-149.
34. Olesky M, Hobbs M, Nicholas RA. 2002. Identification and analysis of amino acid mutations in porin IB that mediate intermediate-level resistance to penicillin and tetracycline in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 46:2811-2820.
35. Olesky M, Zhao S, Rosenberg RL, Nicholas RA. 2006. Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J. Bacteriol. 188:2300-2308.
36. Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN. 2010. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 66:393-401.
37. Shafer WM, Folster JP. 2006. Towards an understanding of chromosomally mediated penicillin resistance in Neisseria gonorrhoeae: evidence for a porin-efflux pump collaboration. J. Bacteriol. 188:2297-2299.
38. Takahata S, Senju N, Osaki Y, Yoshida T, Ida T. 2006. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 50:3638-3645.
39. Tapsall JW. 12 April 2012, accession date. Antimicrobial resistance in Neisseria gonorrhoeae WHO/CDS/CSR/DRS/2001.3, 2001. World Health Organization, Geneva, Switzerland. http://www.who.int/entity/drugresistance/Antimicrobial- resistance-in-Neisseria-gonorrhoeae.pdf.
40. Tapsall JW. 2004. Antimicrobial testing and applications in the pathogenic Neisseria, p 175-188. In Merlino J (ed), Antimicrobial susceptibility testing: methods and practices with an Australian perspective. Australian Society for Microbiology, Sydney, Australia.
41. Tapsall JW, Ndowa F, Lewis DA, Unemo M. 2009. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther. 7:821-834.
42. Tapsall JW, Phillips EA. 1995. The sensitivity of 173 Sydney isolates of Neisseria gonorrhoeae to cefpodoxime and other antibiotics used to treat gonorrhoea. Pathology 27:64-66.
43. Tapsall JW, Ray S, Limnios A. 2010. Characteristics and population dynamics of mosaic penA allele-containing Neisseria gonorrhoeae isolates collected in Sydney, Australia, in 2007-2008. Antimicrob. Agents Chemother. 54:554-556.
44. Tapsall J, et al. 2009. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J. Med. Microbiol. 58(Pt. 5):683-687.
45. Tomberg J, Unemo M, Davies C, Nicholas RA. 2010. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 49:8062-8070.
46. Tomera KM, et al. 2002. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob. Agents Chemother. 46:2895-2900.
47. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall JW. 2009. Phenotypic and genetic characterization of the 2008WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63:1142-1151.
48. Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro. Surveill. 16:pii=19792. http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId=19792.
49. Unemo M, et al. 2012. High-level cefixime- and ceftriaxone-resistant N. gonorrhoeae in Europe (France): novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob. Agents Chemother. 56:1273-1280.
50. Unemo M, Golparian D, Stary A, Eigentler A. 2011. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro. Surveill. 16:pii=19998. http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=19998.
51. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. 2010. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro. Surveill. 15:pii=19721. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19721.
52. Unemo M, Shafer WM. 2011. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann. N. Y. Acad. Sci. 1230:E19-E28.
53. Unemo M, et al. 2007. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacinresistant strain. APMIS 115:231-241.
54. Veal WL, Nicholas RA, Shafer WM. 2002. Overexpression of the MtrC-MtrD-MtrE efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. J. Bacteriol. 184:5619-5624.
55. Whiley DM, Limnios A, Ray S, Sloots TP, Tapsall JW. 2007. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob. Agents Chemother. 51:3111-3116.
56. Whiley DM, et al. 2010. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. J. Antimicrob. Chemother. 65:1615-1618.
57. WHO Western Pacific and South East Asian Gonococcal Antimicrobial Surveillance Programmes. 2011. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009. Commun. Dis. Intell. 35:2-7.
58. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm. Rep. 59(RR-12):1-110.
59. World Health Organization (WHO). 2011. Prevalence and incidence of selected sexually transmitted infections: Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods used by WHO to generate 2005 estimates. World Health Organization, Geneva, Switzerland. ISBN:978 92 4 150245 0.
60. Yokoi S, et al. 2007. Threat to cefixime treatment of gonorrhea. Emerg. Infect. Dis. 13:1275-1277.
61. Zarantonelli L, Borthagaray G, Lee EH, Shafer WM. 1999. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob. Agents Chemother. 43:2468-2472.
62. Zhao S, et al. 2009. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 53:3744-3751.